Oral Non-Incretin Small Molecule
Obesity & Metabolic Disorders
Pre-clinicalActive; Lead compound identified, planning IND-enabling studies
Key Facts
Indication
Obesity & Metabolic Disorders
Phase
Pre-clinical
Status
Active; Lead compound identified, planning IND-enabling studies
Company
About Alaunos Therapeutics
Alaunos Therapeutics is pursuing a dual-track strategy targeting two major therapeutic areas: metabolic health and oncology. Its metabolic program focuses on an oral, non-hormonal small molecule for obesity, with promising preclinical proof-of-concept data showing weight loss and improved body composition in animal models. In parallel, its proprietary hunTR® platform enables rapid discovery and validation of novel TCRs for next-generation TCR-T cell therapies, aiming to create a pipeline of wholly owned oncology candidates.
View full company profile